- Home
- CXAI vs UBX Comparison
CXAI vs UBX Comparison
Compare CXAI & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- UBX
- Stock Information
- Founded
- CXAI N/A
- UBX 2009
- Country
- CXAI United States
- UBX United States
- Employees
- CXAI N/A
- UBX N/A
- Industry
- CXAI EDP Services
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- UBX Health Care
- Exchange
- CXAI Nasdaq
- UBX Nasdaq
- Market Cap
- CXAI 22.4M
- UBX 16.2M
- IPO Year
- CXAI N/A
- UBX 2018
- Fundamental
- Price
- CXAI $1.09
- UBX $0.91
- Analyst Decision
- CXAI
- UBX Strong Buy
- Analyst Count
- CXAI 0
- UBX 3
- Target Price
- CXAI N/A
- UBX $5.33
- AVG Volume (30 Days)
- CXAI 430.4K
- UBX 106.2K
- Earning Date
- CXAI 05-20-2025
- UBX 04-22-2025
- Dividend Yield
- CXAI N/A
- UBX N/A
- EPS Growth
- CXAI N/A
- UBX N/A
- EPS
- CXAI N/A
- UBX N/A
- Revenue
- CXAI $7,142,000.00
- UBX N/A
- Revenue This Year
- CXAI $28.54
- UBX N/A
- Revenue Next Year
- CXAI $66.67
- UBX N/A
- P/E Ratio
- CXAI N/A
- UBX N/A
- Revenue Growth
- CXAI N/A
- UBX N/A
- 52 Week Low
- CXAI $0.76
- UBX $0.85
- 52 Week High
- CXAI $3.82
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- CXAI 49.03
- UBX 37.72
- Support Level
- CXAI $1.04
- UBX $0.86
- Resistance Level
- CXAI $1.21
- UBX $1.23
- Average True Range (ATR)
- CXAI 0.06
- UBX 0.09
- MACD
- CXAI -0.01
- UBX 0.01
- Stochastic Oscillator
- CXAI 33.33
- UBX 14.62
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.